IPI-926: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation Phase I trial in 36 patients with advanced and/or metastatic solid tumors, plus a cohort of 24 patients with basal cell carcinoma (BCC), showed that once-daily oral IPI-926 at doses ranging from 20-200 mg were well tolerated with no grade 4/5 adverse events reported. Grade 3 transaminitis was observed in 4 patients. In 17 evaluable patients with BCC who were naïve to treatment with a hedgehog pathway inhibitor, IPI-926 produced 4 partial responses. Further dose escalation is ongoing to determine the maximum tolerated dose (MTD) of IPI-926. Data were presented at the European Society for Medical Oncology meeting in Milan. ...